Prime Medicine, Inc. (PRME) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
21 Erie Street
Cambridge, MA 02139
United States of America (the)
Phone
617-564-0013
Sector
Healthcare
Industry
Biotechnology
Employees
214
First IPO Date
October 20, 2022
| Name | Title | Pay | Year Born |
| Allan Reine | Chief Executive Officer & Director | 1.07M | 1975 |
| Jeffrey D. Marrazzo | Executive Chair | 140,161 | 1979 |
| Ann L. Lee | Chief Technical Officer | 760,041 | 1962 |
| Svetlana Makhni | Chief Financial Officer | 924,027 | 1984 |
| Keith Michael Gottesdiener | Consultant | 1.02M | 1954 |
| Andrew Anzalone | Co-Founder | 0 | 1987 |
| David R. Liu | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Mohammed Asmal | Chief Medical Officer | 0 | N/A |
| Ryan E. Brown | Chief Legal Officer | 0 | 1979 |
| Niamh Alix | Chief Human Resources Officer | 0 | N/A |
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.